JUBLPHARMA.NS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 07:03):

Stats
Tagesvolumen	46 365.00
Durchschnittsvolumen	555 110
Marktkapitalisierung	109.12B
EPS	INR0 ( 2024-02-01 )
Nächstes Ertragsdatum	( INR0 ) 2024-05-27
Last Dividend	INR5.00 ( 2023-08-10 )
Next Dividend	INR0 ( N/A )
P/E	287.86
ATR14	INR1.006 (0.15%)

Volumen Korrelation

Lang: 0.07 (neutral)

Kurz: -0.62 (weak negative)

Signal:(49.329) Neutral

Jubilant Pharmova Limited Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Jubilant Pharmova Limited Korrelation - Währung/Rohstoff

-0.27
( neutral )

-0.18
( neutral )

0.09
( neutral )

-0.05
( neutral )

-0.28
( neutral )

0.35
( neutral )

Jubilant Pharmova Limited Finanzdaten

Annual	2022
Umsatz:	INR62.19B
Bruttogewinn:	INR43.41B (69.80 %)
EPS:	INR-3.83

FY	2022
Umsatz:	INR62.19B
Bruttogewinn:	INR43.41B (69.80 %)
EPS:	INR-3.83

FY	2022
Umsatz:	INR60.59B
Bruttogewinn:	INR42.72B (70.51 %)
EPS:	INR26.00

FY	2021
Umsatz:	INR59.64B
Bruttogewinn:	INR42.10B (70.60 %)
EPS:	INR52.48

Financial Reports:

No articles found.

Jubilant Pharmova Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR5.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR5.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Jubilant Pharmova Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 1.198 - low (50.00%) | Divividend Growth Potential Score: 2.80 - Decrease likely (44.01%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.857	2003-09-18
Last Dividend	INR5.00	2023-08-10
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	22	--
Total Paid Out	INR57.64	--
Avg. Dividend % Per Year	0.70%	--
Score	1.6	--
Div. Sustainability Score	1.198
Div.Growth Potential Score	2.80
Div. Directional Score	1.999	--

Next Divdend (Est)
(2024-06-03)

INR5.22 Estimate 3.15 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.60

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR3.00	0.37%
2019	INR4.50	0.63%
2020	INR5.00	0.94%
2021	INR5.00	0.78%
2022	INR5.00	0.85%
2023	INR5.00	1.38%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SIYSIL.NS	Dividend Junior	2023-07-24	Semi-Annually	18	1.37%
MEDICAMEQ.NS	Ex Dividend Junior	2023-09-20	Annually	3	0.02%
GULFOILLUB.NS	Dividend Junior	2023-08-25	Annually	11	2.19%
BBTC.NS	Dividend Junior	2023-09-22	Annually	22	0.08%
PRESTIGE.NS	Dividend Junior	2023-09-14	Annually	14	0.25%
KANSAINER.NS	Dividend Junior	2023-05-25	Annually	21	0.49%
EIHAHOTELS.NS	Dividend Junior	2023-07-31	Sporadic	17	0.31%
ADVENZYMES.NS	Dividend Junior	2023-08-04	Annually	8	0.59%
SUBROS.NS	Dividend Junior	2023-08-22	Annually	20	0.22%
NAHARSPING.NS	Dividend Junior	2023-09-08	Annually	18	0.74%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00577	1.500	9.88	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.00701	1.500	-1.033	-1.550	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	1.512	1.000	-0.551	-0.551	[3 - 30]
operatingCashFlowPerShareTTM	35.50	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	35.50	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.673	1.000	2.11	2.11	[0.2 - 0.8]
operatingProfitMarginTTM	0.0588	1.000	-0.825	-0.825	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.198

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	286.36	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.00701	2.50	-0.664	-1.550	[0.1 - 1.5]
freeCashFlowPerShareTTM	35.50	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.735	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	35.50	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-41.30	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0862	1.000	-0.345	0	[0.1 - 0.5]
Total Score				2.80

Jubilant Pharmova Limited

Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.